Business Context and Reporting Period
Company: Superior Surgical Mfg. Co., Inc. (Superior Group of Companies, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and six months ended June 30, 1997
Business Overview: The registrant operates in the healthcare market, manufacturing surgical products. The company reported 7,975,752 common shares outstanding as of the report date.
Key Financial Metrics
| Metric (Six Months Ended June 30) | 1997 | 1996 |
|---|---|---|
| Net Sales | $71,031,804 | $69,569,150 |
| Net Earnings | $4,148,658 | $4,036,173 |
| Earnings Per Share (Diluted) | $0.52 | $0.50 |
| Operating Cash Flow | $5,003,175 | $6,817,042 |
| Cash and Certificates of Deposit | $4,953,513 | $8,278,012 (End of Period 1996) |
| Total Debt (Current + Long-Term) | $16,866,667 | $18,000,000 (End of Period 1996) |
| Cost of Goods Sold Margin | 66.6% | 66.6% |
| Selling & Admin Expense Margin | 23.0% | 23.0% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased approximately 2% for the six months ended June 30, 1997, compared to the prior year. This followed a 3% decline in Q1 1997 due to healthcare market weakness, offset by an 8% increase in Q2 1997 driven by economic momentum.
- Profitability: Net earnings increased 10% for the quarter ended June 30, 1997 ($2,323,602 vs. $2,119,856) and 3% for the six-month period, primarily due to increased sales volume.
- Debt Reduction: Total debt decreased by $1,133,333 to $16,866,667 as of June 30, 1997, due to scheduled repayments. Consequently, interest expense decreased 5% year-over-year.
- Working Capital: Accounts receivable increased 9% to $26,775,251, while inventories remained relatively stable, decreasing less than 1% to $43,970,405. Accounts payable increased 11% due to higher inventory purchases.
- Cash Flow: Net cash provided by operating activities decreased to $5,003,175 from $6,817,042 in the prior year, largely due to an increase in accounts receivable.
Guidance, Outlook, and Risks
- Outlook: Management states that results for the first six months are not necessarily indicative of full-year results. The company plans to continue its capital expenditure program to maintain and improve facilities.
- Liquidity: The company maintains $10,000,000 in available credit under its revolving Credit Agreement. Management believes cash flow from operations and existing credit sources are adequate to meet funding requirements for the foreseeable future.
- Risks: The filing notes that the preparation of financial statements requires estimates and assumptions that could differ from actual results. No specific legal proceedings or defaults were reported.
- Corporate Actions: Shareholders approved a Non-Employee Director Stock Option Plan and ratified the appointment of Deloitte & Touche LLP as auditors at the May 2, 1997 annual meeting.
Investor Verification Checklist
- Verify the sustainability of the Q2 sales rebound (8% increase) given the Q1 weakness attributed to healthcare market conditions.
- Monitor the trend in Accounts Receivable, which grew 9% and contributed to a decrease in operating cash flow.
- Confirm the utilization of the $10,000,000 revolving credit facility and the company's ability to service remaining debt obligations.
- Review the impact of the approved Non-Employee Director Stock Option Plan on future share dilution.
- Assess the stability of the 66.6% Cost of Goods Sold margin in the context of potential raw material price fluctuations.